Find trials
Consejos para buscar

Financial Difficulty in Patients With Blood Cancer

Overview

Información sobre este estudio

The purpose of this study is to analyze the financial difficulties experienced by patients undergoing treatment for multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). It is composed of a patient survey (n=250), a physician survey (n=100), and a practice survey completed by each site enrolling patients onto this study. A subset of enrolled patients (n=35) will be invited to participate in an optional second telephone interview (Appendix D). This study will measure the prevalence of patient-reported financial difficulty, specific financial burdens and resources currently available to patients and from practices to assist with patient financial navigation.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria - Patient:

- Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) or multiple
myeloma (MM)

- Patients' medical records must be available to the registering institution

- Eligible patients must have been prescribed drug-based anticancer therapy, whether
administered orally or by infusion, within the prior 12 months. Specifically, eligible
patients are those who:

- Are presently being treated with infused or orally-administered anticancer
therapy, OR

- Completed infused or orally-administered anti-cancer therapy in the past 12
months, OR

- Were prescribed infused or orally-administered anticancer therapy within the
prior 12 months yet chose to forego treatment

- Not currently enrolled in a clinical trial in which drug is supplied by the study

- Patients with psychiatric illness or other mental impairment that would preclude their
ability to give informed consent or to respond to the telephone survey are not
eligible

- Patients must be able to read and comprehend English or Spanish

Inclusion Criteria - Site:

- Intent to complete the Practice Survey

- Access to patient medical records: Registering institution must have access to patient
medical records, either on site or via request from other institutions, if recruiting
patients at a site (as medical abstraction is required for collecting study data).

- Sites seeking to enroll Spanish- speaking patients must have Spanish speaking staff on
site or through the use of a translation service to be able to conduct the informed
consent discussion in Spanish.

Inclusion Criteria - Physician:

- The physician currently treats patients with chronic lymphocytic leukemia (CLL) and/or
multiple myeloma (MM).

- The physician is a treating physician at a site which has opened this protocol (LCCC
2063) and/or a site which opened the Alliance protocol (A231602CD; ClinicalTrials.gov
Identifier: NCT03870633). Eligible physicians do not need to have their own patients
enrolled onto this protocol.

Eligibility last updated 5/23/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Nandita Khera, M.D., M.P.H.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20539926

Mayo Clinic Footer